Table 1.
Demographics, patient characteristics, and cancer history at baseline.
| Safety population n = 62 |
|
|---|---|
| Males, n (%) | 29 (46.8) |
| Race/ethnicity, n (%) | |
| White | 53 (85.5) |
| Black or African American | 4 (6.5) |
| Asian | 2 (3.2) |
| Other | 3 (4.8) |
| Hispanic or Latino | 4 (6.5) |
| Age, years, median (range) | 62.0 (26–76) |
| Weight, kg, median (range) | 73.7 (50.3–127.4) |
| Height, cm, median (range) | 167.6 (145.5–188.0) |
| Body mass index, kg/m2, median (range) | 26.6 (18.5–46.8) |
| ECOG performance status, n (%) | |
| 0 | 24 (38.7) |
| 1 | 36 (58.1) |
| 2 | 2 (3.2) |
| Concomitant dexamethasone, n (%) | 18 (29.0) |
| Malignancy type, n (%) | |
| Glioblastoma | 20 (32.3) |
| Ovarian cancer | 21 (33.0) |
| Acute myeloid leukemia | 12 (19.4) |
| Non-small-cell lung cancer | 7 (11.3) |
| Other | 2 (3.2) |
ECOG Eastern Cooperative Oncology Group.